These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16564833)

  • 1. Intracameral Vigamox (moxifloxacin 0.5%) is not effective in preventing endophthalmitis in a rabbit model.
    Kodjikian L; Garweg JG
    Am J Ophthalmol; 2006 Apr; 141(4):777; author reply 777-8. PubMed ID: 16564833
    [No Abstract]   [Full Text] [Related]  

  • 2. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model.
    Kowalski RP; Romanowski EG; Mah FS; Yates KA; Gordon YJ
    Am J Ophthalmol; 2005 Sep; 140(3):497-504. PubMed ID: 16083841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model.
    Kowalski RP; Romanowski EG; Mah FS; Yates KA; Gordon YJ
    Am J Ophthalmol; 2004 Jul; 138(1):33-7. PubMed ID: 15234279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracameral moxifloxacin injection to prevent endophthalmitis.
    Lam S
    J Cataract Refract Surg; 2014 Mar; 40(3):509. PubMed ID: 24581787
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of prophylactic intracameral moxifloxacin injection in Japan.
    Matsuura K; Miyoshi T; Suto C; Akura J; Inoue Y
    J Cataract Refract Surg; 2013 Nov; 39(11):1702-6. PubMed ID: 24054967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of endophthalmitis by collagen shields presoaked in fourth-generation fluoroquinolones versus by topical prophylaxis.
    Haugen B; Werner L; Romaniv N; Haymore J; Kleinmann G; Mamalis N; Olson RJ
    J Cataract Refract Surg; 2008 May; 34(5):853-8. PubMed ID: 18471646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of moxifloxacin and levofloxacin topical prophylaxis in a fluoroquinolone-resistant Staphylococcus aureus rabbit model.
    Kowalski RP; Romanowski EG; Mah FS; Sasaki H; Fukuda M; Gordon YJ
    Jpn J Ophthalmol; 2008; 52(3):211-216. PubMed ID: 18661272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory data and statistical evidence in fluoroquinolone study.
    O'Callaghan R; Ohnsman C; Song J
    J Cataract Refract Surg; 2008 Oct; 34(10):1617-8; author reply 1618. PubMed ID: 18812096
    [No Abstract]   [Full Text] [Related]  

  • 9. Experimental intracameral injection of vancomycin microparticles in rabbits.
    Kodjikian L; Couprie J; Hachicha W; Timour Q; Devouassoux M; Builles N; Hartmann D; Fessi H
    Invest Ophthalmol Vis Sci; 2010 Aug; 51(8):4125-32. PubMed ID: 20335605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin.
    O'Brien TP; Arshinoff SA; Mah FS
    J Cataract Refract Surg; 2007 Oct; 33(10):1790-800. PubMed ID: 17889778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic effect of intravenous moxifloxacin in a rabbit model of Staphylococcus epidermidis endophthalmitis.
    Kim JY; Kim SY
    Invest Ophthalmol Vis Sci; 2011 Mar; 52(3):1742-7. PubMed ID: 21169530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reply: To PMID 24054967.
    Matsuura K; Miyoshi T; Suto C; Akura J; Inoue Y
    J Cataract Refract Surg; 2014 Mar; 40(3):509. PubMed ID: 24581786
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery.
    Lane SS; Osher RH; Masket S; Belani S
    J Cataract Refract Surg; 2008 Sep; 34(9):1451-9. PubMed ID: 18721703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical 0.5% moxifloxacin prevents endophthalmitis in an intravitreal injection rabbit model.
    Kowalski RP; Romanowski EG; Mah FS; Yates KA; Gordon YJ
    J Ocul Pharmacol Ther; 2008 Feb; 24(1):1-7. PubMed ID: 18370872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endophthalmitis.
    Bohigian GM
    Ophthalmology; 2008 Feb; 115(2):413-4; author reply 414. PubMed ID: 18243911
    [No Abstract]   [Full Text] [Related]  

  • 16. Decreased postoperative endophthalmitis rate after institution of intracameral antibiotics in a Northern California eye department.
    Shorstein NH; Winthrop KL; Herrinton LJ
    J Cataract Refract Surg; 2013 Jan; 39(1):8-14. PubMed ID: 23036356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery.
    Arbisser LB
    J Cataract Refract Surg; 2008 Jul; 34(7):1114-20. PubMed ID: 18571078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparison of fluoroquinolones to nonfluoroquinolone antibacterial agents for the prevention of endophthalmitis in a rabbit model.
    Kowalski RP; Romanowski EG; Shanks RM; Mah FS
    J Ocul Pharmacol Ther; 2012 Dec; 28(6):604-8. PubMed ID: 22925112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients.
    Espiritu CR; Caparas VL; Bolinao JG
    J Cataract Refract Surg; 2007 Jan; 33(1):63-8. PubMed ID: 17189795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
    Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
    Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.